8th Annual IPF Summit
The 8th IPF Summit returns for its 8th year as the go-to, end-to-end gathering of pulmonary fibrosis drug developers, clinicians and academic thought leaders all dedicated to bringing better drugs to patients faster.
In a year marked by high-profile and unexpected failures, the industry is at a pivotal juncture and every player is focused on maximizing and safeguarding their candidates.
At the 8th IPF Summit, we’re not just acknowledging the turbulence, we’re diving headfirst into it with a bold agenda designed to understand the root causes of the failures that rocked the industry and extract invaluable lessons from previous executives of those companies.
But we’re not just focused on looking back, we’re eager to pave the way for a future of progress. With new candidates, technologies and research all emerging rapidly, the summit serves as the definitive platform for all pulmonary fibrosis drug developers to uncover progress.
From dynamic panel discussions to interactive workshops and exclusive data driven case studies, we’re not just acknowledging the ever-present challenges but providing a forum to collaborate address and seek solutions.
Poster session information:
Poster title: The Potential for Baseline Spirometry Variability to Generate Increased Treatment Response in IPF
Date: Sunday, August 21, 2024
Time: 3:15 p.m. ET
Abstract:
We have noted an unexpectedly high incidence of IPF patients who appear to show increased FVC values over relatively short intervals within clinical trials. Given the progressive nature of the underlying disease and the limited potential for structural change over a matter of weeks we decided to explore this effect to see if this was related to spirometry technique or a learning effect could explain this phenomena.
Join this poster session to learn more about our methods and results from this research.
Presenter
Philip Lake, Ph.D.
Senior Director, Respiratory Solutions at Clario
Phil Lake is a respiratory specialist at Clario who supports global clients. He has held various roles in drug development for 20 years, predominantly focused on respiratory trials. Prior to Clario, Phil worked on several anti-inflammatory agents, dual and triple combination therapy, monoclonal antibody studies, anti-infectives and some of the largest mechanistic studies looking at biomarkers within sputum and biopsy samples at SmithKline Beecham and GlaxoSmithKline. He has experience supporting CROs as a respiratory specialist and as the head of project management. Recently, his concentration has been extensively on rare respiratory diseases, including Cystic Fibrosis and Idiopathic Pulmonary Fibrosis, covering a variety of drug mechanisms and medical devices. Phil was pivotal to some of the first centralized overread studies and is committed to driving improvements in lung function testing.